HDAC Inhibition Blunts Ischemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy

BACKGROUND: Reperfusion accounts for a substantial fraction of the myocardial injury occurring with ischemic heart disease. Yet, no standard therapies are available targeting reperfusion injury. Here, we tested the hypothesis that SAHA, a histone deacetylase (HDAC) inhibitor FDA-approved for cancer...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Xie, Min, Kong, Yongli, Tan, Wei, May, Herman, Battiprolu, Pavan K., Pedrozo, Zully, Wang, Zhao, Morales, Cyndi, Luo, Xiang, Cho, Geoffrey, Jiang, Nan, Jessen, Michael E., Warner, John J., Lavandero, Sergio, Gillette, Thomas G., Turer, Aslan T., Hill, Joseph A.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3984913/
https://ncbi.nlm.nih.gov/pubmed/24396039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.113.002416
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares